Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans

(2022) Florian B. Mayr et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Jill M. Ferdinands et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021

(2022) Sara E. Oliver et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

(2021) Mark G. Thompson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

(2021) Peter J. Embi et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT